Crossmark

Cost-effectiveness analysis of polymyxin B versus colistin for treating patients with carbapenem-resistant gram-negative bacterial infections

Published Online: 2024-10-09

Authors

Wang, Ye

Yu, Lingyan

Zhu, Jianping

Liang, Gang

Liu, Jieqiong

Zheng, Ying

Zhao, Yuhua

Yu, Zhenwei
Funding

Funding for this research was provided by:

Zhejiang Pharmaceutical Association (2022ZYJ19)

Zhejiang Pharmaceutical Association (2021ZYY02)
License Information

Text and Data Mining valid from 2024-10-09

Version of Record valid from 2024-10-09
More Information

Article History

Received: 7 March 2024

Accepted: 25 September 2024

First Online: 9 October 2024

Declarations

:

: The authors declare no competing interests.

Document is current